Who are DCV/ASV/BMS-791325's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): OBV/PTV/r and DSV.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dcv-asv-bms-791325.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

DCV/ASV/BMS-791325 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DCV/ASV/BMS-791325 (DCV/ASV/BMS-791325) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct-acting antiviral combination (NS5A inhibitor + NS3 protease inhibitor + NS5B polymerase inhibitor). Area: Virology / Hepatology.

phase 3 Direct-acting antiviral combination (NS5A inhibitor + NS3 protease inhibitor + NS5B polymerase inhibitor) HCV NS5A, NS3/4A protease, NS5B polymerase Virology / Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

DCV/ASV/BMS-791325 (DCV/ASV/BMS-791325) — Bristol-Myers Squibb. This is a three-drug combination of direct-acting antivirals (DCV, ASV, and BMS-791325) that inhibit hepatitis C virus NS5A, NS3 protease, and NS5B polymerase respectively to block viral replication.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DCV/ASV/BMS-791325 TARGET	DCV/ASV/BMS-791325	Bristol-Myers Squibb	phase 3	Direct-acting antiviral combination (NS5A inhibitor + NS3 protease inhibitor + NS5B polymerase inhibitor)	HCV NS5A, NS3/4A protease, NS5B polymerase
OBV/PTV/r and DSV	OBV/PTV/r and DSV	Hannover Medical School	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A, NS3/4A protease, NS5B polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct-acting antiviral combination (NS5A inhibitor + NS3 protease inhibitor + NS5B polymerase inhibitor) class)

Bristol-Myers Squibb · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DCV/ASV/BMS-791325 — Competitive Intelligence Brief. https://druglandscape.com/ci/dcv-asv-bms-791325. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing